Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical
bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and
feasible for patients with very high-risk solid tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins